Experts Perspectives: Navigating Newly Diagnosed MM to Early Relapse - Episode 2

Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma

October 18, 2024

Ajay Chari, MD, Noopur S. Raje, MD, Adriana Rossi, MD, Weill Cornell Medical College, Natalie Callander, MD, Tom Martin, MD

Panelists discuss whether daratumumab quadruplet induction regimens should be considered the new standard of care for newly diagnosed transplant-eligible patients and explore scenarios in which a triplet induction regimen might still be appropriate. They also review the findings from the ISKIA and GMMG-CONCEPT trials, including considerations for using isatuximab-carfilzomib (IsaKRd) over D-VRd.

EP. 1: Transplant Eligible, Newly Diagnosed Multiple Myeloma: PERSEUS & CASSIOPEIA Study Updates

Now Viewing

EP. 2: Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma

EP. 3: Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma: CEPHEUS, IMROZ, and BENEFIT Studies

EP. 4: MRD Negativity as a Trial Outcome and Its Use in Clinical Practice

EP. 5: Use of CAR T-cell Therapies for Early Relapse Multiple Myeloma

EP. 6: Considerations for Triplet or Quadruplet Regimens in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

In your clinical opinion, are daratumumab quadruplet induction regimens the new standard of care for newly diagnosed (transplant-eligible) patients? Are there patients for whom you would still consider a triplet induction regimen?
Could you also review the ISKIA & GMMG-CONCEPT trials and findings? Are there any clinical scenarios where you would consider an isatuximab-carfilzomib (IsaKRd) quadruplet over D-VRd?